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SUMMARY
Field studies show an association between schistosome infec-
tion and atopy, but the effects of anti-helminthic treatment on
this association have not yet been investigated in human
populations with different schistosome endemicity levels.
This study aimed to compare the effects of anti-helminthic
treatment on responses directed against the house dust mite
Dermatophagoides pteronyssinus (Derp1) and Schistosoma
haematobium in Zimbabwean populations living in high and
low schistosome infection areas. Derp1- and schistosome-
specific IgE and IgG4 antibodies were quantified by ELISA
before and 6 weeks after anti-helminthic treatment. Following
treatment, there were changes in the immune responses, which
varied with place of residence. After allowing for the effects
of sex, age and baseline infection intensity, there was no sig-
nificant treatment effect on the change in anti-schistosome
IgE and IgG4 in the high infection area. However, the anti-
schistosome IgE ⁄ IgG4 ratio increased significantly, while
anti-Derp1 IgE responses decreased as a result of treatment.
In the low infection area, treatment resulted in a significant
increase in anti-worm IgE levels, but there was no significant
treatment effect on anti-schistosome or anti-Derp1 IgE ⁄ IgG4
ratios. Thus, the study shows that the level of schistosome
endemicity affects the host responses to schistosome and mite
antigens following anti-helminthic treatment.
Keywords atopy, Dermatophagoides pteronyssinus, IgE,
IgG4, infection, praziquantel, Schistosoma haematobium
INTRODUCTION
Schistosomiasis remains one of the most important tropical
human infections in terms of parasite-induced morbidity
and mortality (1). The disease burden accounts for up to
70 million disability-adjusted life years (DALYs) annually
(1), and it continues to threaten people in developing coun-
tries because of poor sanitation and lack of safe water
sources. On the other hand, some epidemiological and ani-
mal studies suggest protective effects of helminth parasites
including schistosomes and gastrointestinal nematodes
against allergy and autoimmune disorders (2–4). The exact
mechanisms involved in the relationship between parasitic
infections and allergy ⁄ autoimmune disorders are poorly
understood (5–7). There are studies suggesting that parasitic
infections are protective (2,8) as well as studies suggesting
the opposite (9). Possible explanations of these contrasting
findings include differences in the intensity of the parasite
infection, the parasite species and host genetic factors (3,5).
Nonetheless, the relationship between helminth infections
and allergy is believed to have an immunological basis. The
general consensus is that exposure to either helminth para-
sites or allergens induces effector T-helper cell type 2 (Th2)-
mediated immunity characterized by high IgE titres.
However, in the case of helminth infection, these immune
responses are modulated and there is evidence, at least in
schistosome infection, to suggest that Th2 cells are
impaired, with reduced responsiveness with chronicity of
infection [rev. by Maizels et al. (10)].
The current method of control for schistosome infection
is the treatment of infected people with the anti-helminthic
drug praziquantel (PZQ). Although there have been
several detailed, albeit conflicting, studies on the effects of
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anti-helminthic treatment for intestinal helminths on atopy
(9,11–13), there are no extensive studies on the effects of
the anti-helminthic PZQ in Schistosoma haematobium
infections. In the light of the fact that the different life his-
tories and biologies of helminths (e.g. nematodes vs. trem-
atodes) result in different host-immunomodulatory
dynamics (14), it is important to determine the effects of
PZQ treatment for S. haematobium infections in endemic
areas. Previous studies have shown that treatment for
schistosome infections alters schistosome-specific immune
responses (15–18). Furthermore, we have recently demon-
strated that atopic responses are inversely associated with
schistosome infection levels (19). However, it is currently
unknown how different pre-treatment schistosome infec-
tion levels impact on atopic reactivity following anti-hel-
minthic treatment. Thus, the aim of this study was to
determine whether different pre-treatment schistosome
infection levels and transmission dynamics altered the
effects of PZQ treatment on allergen-specific antibody
responses. To investigate this, the study was conducted in
two villages with differing schistosome infection levels.
Levels of IgE and IgG4 against schistosome adult worm
and egg antigens as well as those against the house dust
mite Dermatophagoides pteronyssinus (Derp1) allergen –
one of the most important allergen in clinical allergy (20)
and prevalent in Zimbabwe (21) – were quantified before a
single dose of PZQ was given and 6 weeks later. The aim
was to investigate the dynamics of the relationship
between atopic responses and schistosome-specific
responses when pre-existing schistosome infection is
cleared and newly acquired infection (if any) not yet pat-
ent (22) in human populations. The study focused on IgE
and IgG4 antibody responses directed against schisto-
somes and the house dust mite because high levels of par-
asite-specific IgE are associated with resistance to
infection ⁄ re-infection while parasite-specific IgG4 is
believed to be a modulator of IgE effector responses
(18,23,24). These antibodies are also important in clinical
allergy where allergen-specific IgE antibodies are indicative
of an allergic phenotype (25), while IgG4 antibodies are
associated with improvement in allergic symptoms follow-
ing immunotherapy or natural recovery (26–28). The rela-
tive proportions of these antibodies (or the balance
between them) are therefore a key feature in humoral
immunity against schistosomes (29–31) or predictors of
clinical manifestations of atopy (28,32). We have already
demonstrated in a previous study that atopy is slightly
more prevalent in people resident in the low schistosome
infection area compared to the high infection area (19).
Furthermore, we reported that the levels of atopic
responses were negatively associated with schistosome
infection intensity. Thus, we hypothesize that the effect of
treatment on the levels of schistosome-specific and aller-
gen-specific IgE and IgG4 responses will vary between the
villages of different levels of schistosome infection.
MATERIALS AND METHODS
Study design
The study was comparative, contrasting the effects of PZQ
treatment on the levels of atopic responses as well as schis-
tosome-specific antibody responses in high vs. low schisto-
some infection villages. Differences in infection levels
reflect differences in infection transmission rates and his-
tory of infection (33). Subjects in the high infection village
accumulate infection more rapidly, acquiring higher infec-
tion intensities at a younger age than their counterparts in
the low infection village (33).
The two villages included in this study are classified as
a high infection area (schistosome prevalence > 50%) and
a low infection area (schistosome prevalence < 10%) based
on the World Health Organization’s guidelines for areas
endemic for S. haematobium infection (34). WHO recom-
mends PZQ treatment schedules based on these transmis-
sion categories. Thus, the comparison made in this study
is a representation of the field setting for the different lev-
els of schistosome endemicity, allowing the comparison of
the effects of PZQ treatment in these different popula-
tions.
Study area and population
The study was conducted in two villages, Magaya and
Chitate, in the Mashonaland East Province of Zimbabwe
where S. haematobium is endemic. In this area, as in most
rural regions in Zimbabwe (35,36), the prevalence of soil-
transmitted helminths and Schistosoma mansoni is low,
while S. haematobium is the most prevalent helminth infec-
tion. In addition, this study area was classified under the
sporadic transmission regions with low Plasmodium trans-
mission and malaria by a revised stratification based on
national parasite prevalence surveys (37,38), Health Man-
agement Information Systems (HMIS) data, entomological
data and expert opinion.
The study villages are in close proximity within a 10 km
range of each other, and villagers are of similar ethnicity
(Shona) and socioeconomic background (rural subsistence
farmers). Safe water and sanitation coverage are equally
poor in the villages (as assessed by questionnaire). The
only difference between the villages is the seasonality of
the rivers that provide habitats for schistosome interme-
diate host snails. Magaya village is characterized by
perennial rivers that lead to high transmission rates of
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schistosome parasites compared to Chitate village, which
is characterized by seasonal streams. In addition, house-
holds in Magaya are built along rivers, whereas in Chitate,
they are more dispersed and built further from the rivers
(surveyed by GPS mapping). Human contact with water
potentially harbouring cercariae, the infective stage of
schistosomes, is frequent (assessed by questionnaire) in
this area because of insufficient safe water and sanitation
facilities.
Ethical statement
Permission to conduct the study in the region was
obtained from the Provincial Medical Director, while insti-
tutional and ethical approvals were received from the Uni-
versity of Zimbabwe and the Medical Research Council of
Zimbabwe, respectively. All participants had the aims and
procedures of the project explained fully in the local lan-
guage, Shona, and written consent was obtained before
enrolment into the study. For young children, written con-
sent was obtained from parents ⁄ guardians. After collection
of all samples, all compliant participants were offered
anti-helminthic treatment with the recommended dose of
PZQ (40 mg ⁄kg of body weight).
Sample collection
Stool and urine samples were collected on three consecu-
tive days for the diagnosis of schistosome and geo-hel-
minth infections. S. mansoni and geo-helminths were
diagnosed by stool egg count via the Kato Katz technique
(39), while S. haematobium was diagnosed and quantified
via urine filtration followed by microscopic egg count
(40). Infection intensity was calculated as the mean egg
count obtained from two or three specimens. Venous
blood was collected, from each participant, into silicone-
coated tubes without anticoagulant and was used to
obtain sera for antibody assays. Malaria status was deter-
mined by blood smears and confirmed by a serological
Paracheck dipstick (Orchid Biomedical systems, Goa,
India).
Inclusion criteria
To be included in the study, participants had: (i) to be life-
long residents of the village (assessed by questionnaire);
(ii) to not previously have received anti-helminthic treat-
ment; (iii) to provide, at baseline and 6 weeks post-treat-
ment, urine and stool samples for helminth diagnosis and
blood samples for serological assays; (iv) to be negative
for geo-helminth or S. mansoni infections; and (v) to be
schistosome egg negative 6 weeks after anti-helminthic
treatment if they were treated with PZQ. A total of 325
individuals fulfilled the inclusion criteria (Figure 1) and
formed the study populations. 61 individuals who refused
treatment (40 from the high infection areas and 21 from
the low infection area) for religious reasons but wished to
remain in the study effectively formed the untreated con-
trol groups. Characteristics of the study populations are
detailed in Table 1.
Antigens
Lyophilized soluble S. haematobium adult worms (males
and females at a ratio of 1 : 1) (SWAP) and egg antigens
(SEA) were obtained from the Theodor Bilharz Institute
(Giza, Egypt) and reconstituted as recommended by the
manufacturer. The parasite strain is one used for previous
immuno-epidemiological studies in Zimbabwe (15,16).
Natural Derp1 allergen (NA-DP-1-2, purified by affinity
chromatography) was obtained from Indoor Biotechnolo-
gies Ltd (Charlottesville, VA, USA).
Antibody assays
A standard indirect enzyme-linked immunosorbent assay
(ELISA) (33) was optimized and used to quantify
the levels of antibodies (IgE and IgG4) directed against
Figure 1 Flow diagram showing numbers
of recruited and followed up participants.
The highlighted boxes represent people
included in the present analysis (treated in
plain grey and untreated in grey texture).
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S. haematobium adult worm antigen (SWAP), SEA and
Derp1 allergen. ELISAs for pre- and post-treatment sam-
ples were conducted in the same period of time and by the
same person to minimize experimental variations. Serum
samples for pre- and post-treatment were not run on the
same plate but six individual sera were run on each
ELISA plate and these were statistically comparable. Fur-
thermore, a pool of responders (positive controls) was run
on each plate and readings were comparable across plates,
that is, the % CV was <20% for all comparisons and read-
ings were below the critical values (see 41); therefore, no
correction factor was used.
ELISAs for schistosome antigens
Microtitre plates were coated overnight at 4C with
100 lL ⁄well of antigen at 5 lg ⁄mL for SWAP and
10 lg ⁄mL for SEA in carbonate bicarbonate buffer
(pH = 9Æ6) and then washed once with PBS 0Æ03% Tween-
20 (which was used for all subsequent washes). Plates were
blocked with 5% skimmed milk in PBS ⁄ 0Æ05% Tween-20
for 2 h before 100 lL of the serum samples were added
diluted at 1 : 20 for IgE, 1 : 100 for IgG4 anti-SWAP and
1 : 400 for IgG4 anti-SEA. Plates were incubated for 2 h
at a temperature of 37C. After washing three times,
100 lL of anti-human horseradish peroxide-conjugated
IgE (Sigma, London, UK) or IgG4 (The Binding Site
Birmingham, UK) diluted at 1 : 1000 except for IgG4
anti-SWAP (1 : 500) and IgE anti-SWAP (1 : 250). After
1-h incubation at 37C followed by six washes, 100 lL of
the substrate (ABTS; Southern Biotech, Birmingham, AL,
USA) was added. The reaction was stopped after 15-min
incubation at room temperature for IgG4 and 30 min at
37C for IgE, using 25% HCL; absorbance readings of all
wells were performed at 405 nm. All samples were assayed
in duplicate, and a blank control containing no sera was
included (also in duplicate) on each plate and the back-
ground absorbance of reagents in the absence of serum
was subtracted from all readings.
ELISA for Derp1 allergen
The protocol above described was used with modifications:
plates were coated with 50 lL ⁄well of Derp1 at 5 lg ⁄mL
and samples diluted 1 : 10. Detection antibodies (IgE from
Sigma and IgG4 from The Binding Site) were diluted
1 : 1000, and the reaction time for the substrate was
30 min at 37C.
Statistical analysis
In this study, parametric tests were performed rather than
non-parametric tests as these are more powerful and allow
studying the relationship between epidemiological variables
while controlling for confounding factors. However, the raw
data were transformed to fulfil the assumptions of paramet-
ric tests [normal distribution of residuals, homogeneity of
variance, linearity and orthogonality (42)]. Thus, antibody
data were square root-transformed while infection intensity
was log10(x + 1)-transformed and these gave normally dis-
tributed residual plots (of the otherwise skewed raw data).
Age was categorized into three age groups reflecting epide-
miological patterns of infection to allow the non-linear rela-
tionship between age and infection to be fitted in the
models used (42). These age groups and the sample sizes for
each group in each village and treatment status are illus-
trated in Table 1. Schistosome infection prevalence and
intensity at baseline were compared between the two villages
by Pearson chi-squared test and analysis of variance (ANO-
VA), respectively. To test whether there were significant
changes in antibody levels between the two time points
(baseline and 6 weeks post-treatment), and whether these
Table 1 Description of the study population
High infection area Low infection area
Treated Untreated Treated Untreated
Total, N 184 40 80 21
Age groups
Age group 1 (6–10 years) 105 30 42 16
Age group 2 (11–15 years) 60 5 22 2
Age group 3 (16+) 19 5 16 3
Sex ratio (M : F) 0Æ8 1Æ7 0Æ6 0Æ9
Mean age (range) 12Æ8 years (6–84) 12 years (6–62) 17 years (6–86) 13Æ3 years (6–55)
Mean infection intensity at baseline (range) 26Æ2 (0–502Æ3)
GM: 0Æ62
5Æ9 (0–50Æ7)
GM: 0Æ28
0Æ43 (0–20)
GM: 0Æ05
0Æ8 (0–8Æ7)
GM: 0Æ11
Egg positive cases at baseline (prevalence) 97 (52Æ7%) 10 (25%) 5 (6Æ25%) 3 (14Æ3%)
Infection levels [mean egg count ⁄ 10 mL urine and geometric mean (GM)], sex ratio (M: male and F: female) and age range for treated and
untreated individuals selected from the high and low infections areas
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were owing to treatment or other variables (age, sex, village,
baseline infection), a repeated measures general linear
model (GLM) was conducted. In this model, antibody levels
(square root-transformed) were the dependent variables
(two levels, pre- and post-treatment), while the independent
variables were age (categorical, group 1, 6–10 years; group
2, 11–15 and group 3, 16+), sex (categorical, male ⁄ female),
village (categorical, HIA ⁄LIA), infection intensity at base-
line (covariate, log10x + 1-transformed) and treatment sta-
tus (categorical, treated ⁄untreated). Sequential sum of
squares (type I) was used in this model to allow the hierar-
chical decomposition of the sources of variation in the
dependent variable because some independent variables
share information [non-orthogonality, see (42) for review].
The variable ‘treatment status’ was entered last in this model
to allow for the effects of all other independent variables
before testing for the effects of treatment. As this initial
analysis showed that the changes in some antibody levels
differed between the villages of residence, the data were par-
titioned by village to test the hypothesis that the effect of
treatment on the magnitude of antibody change is depen-
dent on cumulative history of infection. Thus, the effect of
treatment on the magnitude of antibody and ratios changes
(determined as post-treatment values minus pre-treatment
values) was determined by the analysis of variance in each
village, allowing for the variations owing to host age, sex
and baseline infection intensity. In this analysis, the sequen-
tial sums of squares were also used to calculate the test
statistics with treatment status entered last in the model. To
test the hypothesis that baseline infection intensity affects
the magnitude of change in antibody levels, the variable
‘infection intensity’ was entered after ‘sex’ and ‘age’ in this
model.
All statistical analyses were conducted in PASW (IBM
corporation, Armonk, NY, USA) statistics 17, and P-val-
ues <0Æ05 were considered significant.
RESULTS
Baseline infection intensity and prevalence differ signifi-
cantly between the two villages
At baseline, schistosome infection levels were significantly
higher in Magaya than Chitate with a prevalence of 47Æ5%
vs. 9Æ3% (v2 = 100Æ5, d.f. = 1, P < 0Æ001) and mean infec-
tion intensity of 26Æ2 eggs per 10 mL vs. 0Æ9 eggs per
10 mL (F1, 580 = 79Æ748, P < 0Æ001), respectively. When
partitioned by age groups, there were significant differ-
ences in infection levels in the two areas in younger age
groups (Figure 2). There was an earlier peak of infection
in Magaya than Chitate, although the peak in Chitate was
not statistically significant, and a significant age and
village interaction (F1, 579 = 6Æ963, P = 0Æ009).
Overall change in antibody levels between the two time
points
Results from the repeated measures GLM analysis
between pre- and post-treatment antibody levels (Table 2)
show significant changes in anti-schistosome and anti-
Derp1 antibody responses over time (i.e. time between
baseline and 6 weeks post-treatment). Although there were
changes between the two time points in most schistosome
antibody levels as well as in anti-allergen responses, only
changes in anti-SWAP IgE and Derp1 IgE were related to
Figure 2 Prevalence and infection intensity (egg count per 10ml)
by age in the study area. Overall infection intensity (a) and
prevalence (b) for the population from which the study cohorts
were chosen. Infection levels (log-transformed for infection
intensity and percentage of positive cases for prevalence) are
plotted against age groups in the high infection area (doted line)
and the low infection area (plain line). Bars represent standard
error of the means for infection intensity and 95% CI for the
prevalence. Asterisks represent significant differences at P < 0Æ01
in each group between the two villages.
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treatment as shown by the significant time*PZQ treatment
interaction in Table 2. As a result of the significant change
in anti-SWAP IgE, the ratio IgE ⁄ IgG4 also increased sig-
nificantly in treated people compared to untreated people.
However, this analysis showed that the temporal changes
differed between the two villages (significant interaction
time*village). Thus, for SWAP IgE, the increase was
greater in the high transmission village; for SEA-IgE and
the ratio IgE ⁄ IgG4 SEA, there was a slight increase in the
high transmission village and a decrease in the low
transmission village; for Derp1 IgE and the ratio
IgE ⁄ IgG4 –Derp1, the decline was greater in the high
transmission village; and for Derp1 IgG4, the increase was
greater in the low transmission village. A further analysis
was conducted (as detailed below) to determine the effect
of treatment in each village.
Differences in antibody responses between treated and
untreated people from different villages
The data were partitioned by residential village and the
change in antibody levels analysed by ANOVA after allow-
ing for the effects of host age, sex and baseline infection
intensity. This analysis (Table 3 and Figures 3 and 4)
showed that in the high infection area, although no signifi-
cant difference occurred in the individual antibodies (Fig-
ure 3), the ratio anti-SWAP IgE ⁄ IgG4 rose significantly
while that of anti-SEA was significantly lower in treated
vs. untreated people (Figure 4). Derp1-specific IgE levels
declined significantly in treated people compared to
untreated people in the high infection area. In the low
infection area, only the change (increase) in SWAP IgE
was significantly different between treated and untreated
people and there was no significant difference in the levels
of allergen-specific responses in treated vs. untreated
people (Figure 3).
Baseline infection intensity was significantly associated
with the treatment-induced antibody change for anti-schis-
tosome responses but not anti-Derp1 responses in the high
infection area. As shown in Table 3, there were significant
effects of infection intensity on IgE and IgG4 against the
adult worm and egg antigens (positive b coefficients: posi-
tive association) as well as the ratio IgE ⁄ IgG4 against the
egg antigens (negative b coefficient: negative association)
in the high infection area.
DISCUSSION
With the increasing calls for concerted helminth control
efforts to meet Millennium Development Goal 6, it is
important that the consequences of anti-helminthic treat-
ment are fully understood. On the one hand, there isTa
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mounting evidence that anti-helminthic treatment not
only transiently reduces infection, but also has longer
term benefits in terms of morbidity control and the
development of parasite-specific immune responses
associated with resistance to re-infection (18,43–45). On
the other hand, there are several studies suggesting that
anti-helminthic treatment increases the incidence of ato-
pic reactivity (11,12), although there are some studies
showing the opposite effect (9). Heterogeneities in para-
site transmission dynamics may influence the effect of
anti-helminthic treatment on atopic reactivity as well as
parasite-specific responses. Thus, we investigated the
effect of PZQ treatment on anti-mite as well as anti-
schistosome IgE and IgG4 antibody responses in two
villages of differing schistosome infection levels. The two
villages selected represented two categories of schistosome
endemicity defined by the WHO (34), that is, an area of
low infection levels (prevalence <10% as occurs in Chi-
tate) and an area of high infection (prevalence >50% as
occurs in Magaya), which guide anti-helminthic treatment
schedules. In a previous study, we demonstrated that
there was a difference in the levels of atopic responses,
which was related to current levels of schistosome infec-
tion (19). We also demonstrated significant differences in
the levels of schistosome-specific and Derp1-specific IgE
and IgG4 responses.
This current study evaluated the effects of anti-helmin-
thic treatment in these villages because the WHO guide-
lines recommend treatment in villages with both these
levels of schistosome endemicity. Our study shows that
6 weeks after anti-helminthic treatment, there were differ-
ences in schistosome and Derp1-specific antibody changes
in the two villages. The enrolment of untreated controls in
this group enables the distinction to be made between
treatment-related changes in the immune responses and
temporal differences occurring owing to the natural devel-
opment of immune responses (especially in infected
untreated people) and potential stochastic variations.
Indeed, there were temporal differences in the levels of
immune responses, but only differences in treated people
compared to untreated people could be attributed to PZQ
treatment.
Treatment was associated with a significant increase in
the ratio IgE ⁄ IgG4 against schistosome adult worm
Table 3 Results from a multivariate general linear model (GLM) analysis of the effects of treatment, by village, on the difference between
pre- and post-treatment antibody levels
Dependent
Sex
F (P)
Age
F (P)
Infection intensity
F (b) (P)
Treatment (PZQ)
F (P)
High infection area
Anti-schistosome responses SWAP IgE 0Æ699 (0Æ404)f > m 5Æ511 (0Æ005) 21Æ882 (0Æ079) (<0Æ001) 1Æ996 (0Æ159)T > U
SWAP IgG4 0Æ864 (0Æ354)f < m 9Æ212 (<0Æ001) 27Æ121 (0Æ084) (<0Æ001) 1Æ087 (0Æ298)T > U
SWAP IgE ⁄ IgG4 0Æ048 (0Æ827)f < m 1Æ902 (0Æ152) 1Æ810 ()16Æ99) (0Æ175) 5Æ916 (0Æ016)T > U
SEA-IgE 6Æ509 (0Æ011)f > m 1Æ229 (0Æ294) 19Æ913 (0Æ09) (<0Æ001) 0Æ522 (0Æ471)T > U
SEA-IgG4 0Æ115 (0Æ735)f > m 0Æ924 (0Æ399) 6Æ824 (0Æ035) (0Æ01) 3Æ293 (0Æ071)T > U
SEA-IgE ⁄ IgG4 0Æ764 (0Æ383)f > m 2Æ297 (0Æ103) 3Æ981 ()22Æ7) (0Æ047) 7Æ717 (0Æ006)T<U
Anti-allergen responses Derp1 IgE 4Æ787 (0Æ030)f < m 2Æ286 (0Æ104) 0Æ108 (0Æ006) (0Æ742) 5Æ617 (0Æ019)T > U
Derp1 IgG4 0Æ368 (0Æ545)f < m 2Æ088 (0Æ126) 2Æ164 ()0Æ034) (0Æ143) 2Æ478 (0Æ117)T < U
Derp1 IgE ⁄ IgG4 0Æ716 (0Æ398)f < m 3Æ945 (0Æ021) 2Æ726 (7Æ875) (0Æ100) 3Æ858 (0Æ051)T > U
Low infection area
Anti-schistosome responses SWAP IgE 1Æ217 (0Æ273)f < m 11Æ314 (<0Æ001) 0Æ003 (0Æ022) (0Æ96) 5Æ982 (0Æ016)T > U
SWAP IgG4 1Æ576 (0Æ212)f < m 4Æ413 (0Æ015) 0Æ013 ()0Æ017) (0Æ909) 0Æ98 (0Æ325)T < U
SWAP IgE ⁄ IgG4 0Æ754 (0Æ388)f > m 1Æ079 (0Æ344) 0Æ00 (4Æ442) (0Æ988) 0Æ428 (0Æ514)T > U
SEA-IgE 0Æ155 (0Æ695)f < m 16Æ568 (<0Æ001) 1Æ462 ()0Æ109) (0Æ23) 3Æ914 (0Æ051)T > U
SEA-IgG4 0Æ559 (0Æ457)f > m 5Æ395 (0Æ006) 1Æ991 ()0Æ095) (0Æ161) 0Æ000 (0Æ993)T=U
SEA-IgE ⁄ IgG4 0Æ756 (0Æ387)f < m 1Æ053 (0Æ353) 0Æ009 ()1Æ549) (0Æ926) 0Æ438 (0Æ51)T > U
Anti-allergen responses Derp1 IgE 2Æ485 (0Æ118)f < m 5Æ864 (0Æ004) 0Æ952 ()0Æ048) (0Æ332) 0Æ462 (0Æ498)T < U
Derp1 IgG4 10Æ005 (0Æ002)f < m 18Æ219 (<0Æ001) 0Æ065 (0Æ058) (0Æ800) 0Æ503 (0Æ48)T > U
Derp1 IgE ⁄ IgG4 0Æ343 (0Æ56)f < m 2Æ305 (0Æ105) 0Æ054 ()0Æ26) (0Æ817) 1Æ626 (0Æ205)T < U
F (and P-) values from multivariate GLM analysis of the effect of treatment on the magnitude of change in antibody responses (and ratios)
in the high and low infection areas after allowing for the effects of host age, sex and infection intensity. Significant P-values are highlighted
in bold and significant b coefficients (for the direction of the effect of infection intensity) are shaded grey and given in bold. The dependent
variable represents the difference between post-and pre-treatment antibody levels for each isotype. SWAP, soluble worm antigen prepara-
tion; SEA, soluble egg antigen; Derp1, Dermatophagoides pteronyssinus allergen 1; PZQ, praziquantel.; T, treated; U, untreated; m, male; f,
female.
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antigens in the high infection area. High levels of para-
site-specific IgE have been associated with resistance to
schistosome infection while IgG4 are associated with
susceptibility (18,23). The increase in the levels of
anti-SWAP IgE over IgG4 (ratio IgE ⁄ IgG4) following
chemotherapy in this study supports a role of PZQ in
the development of putatively protective acquired immu-
nity as it has been reported previously (18,23). In the
low infection area, these changes are less apparent possi-
bly due to low levels of infection (and therefore low lev-
els of parasite-specific antibodies) (46), but levels of anti-
worm IgE antibodies increased significantly in treated
individuals in this area. This is consistent with the result
showing a positive association between infection intensity
and the magnitude of change in antibody levels (repre-
sented by the b value from the ANOVA) in the high infec-
tion area, which is not apparent in the low infection
area, where infection levels may be too low for a distinct
association to be detectable.
Variations in anti-schistosome egg antibody responses
following PZQ treatment have been reported (43) and
studies on Schistosoma japonicum associated anti-egg IgE
responses with resistance to re-infection (24). In the pres-
ent study, the magnitude of increase in the IgE ⁄ IgG4 ratio
against SEA in the high infection area was lower in trea-
ted than untreated people, reflecting an increase in both
SEA-IgE and SEA-IgG4 following treatment. Further-
more, this ratio was negatively associated with pre-treat-
ment infection intensity, suggesting that, in contrast to
anti-worm responses, SEA-IgG4 increased more than
SEA-IgE in people heavily infected prior treatment. This
Figure 3 Comparison of changes in antibody levels. Mean anti-
body changes for the study populations are shown for treated
(black columns) and untreated (white columns) people in the
high infection area (a) and the low infection area (b) with
standard error of means. Antibody changes are calculated as
the difference between post-treatment square root-transformed
levels and pre-treatment square root-transformed levels.
Asterisks represent significant differences between treated and
untreated people at P < 0Æ05, which are obtained from the
analysis of variance after allowing for the variation owing to
the potential confounding variables – host age, sex and pre-
treatment infection intensity.
Figure 4 Comparison of changes in the ratios. Mean changes in
ratios IgE ⁄ IgG4 for treated (black columns) and untreated (white
columns) people are shown for the high infection area (a) and the
low infection area (b) with standard error of means. Asterisks rep-
resent significant differences between treated and untreated people
at *P < 0Æ05 and **P < 0Æ01 obtained from the analysis of vari-
ance after allowing for the variation owing to the potential con-
founding variables – host age, sex and pre-treatment infection
intensity.
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is suggestive of, although not conclusive evidence for, the
immunomodulatory role of IgG4 (30) following the rapid
release of parasite ‘inflammatory’ egg antigens after PZQ
treatment.
Similar to schistosome-specific responses, there were
temporal differences in the allergen-specific responses.
However, only changes in anti-Derp1 IgE levels in the
high infection area differed in treated vs. untreated people.
In the treated people, anti-Derp1 IgE levels declined sig-
nificantly compared to untreated people. However, there
were no significant changes in the ratio of the anti-Derp1
IgE ⁄ IgG4, possibly because of the increase in anti-
DerpIgG4. The reason for this increase, which occurred
in individuals with low or no infection at baseline
(treated and untreated), requires further investigations [e.g.
seasonal variations (47)].
IgE mediates the pathological manifestations of allergy
(25,26), and we have shown that these antibodies correlate
with skin sensitization in this population (19). Thus, a
decline in the levels of this antibody may result in reduced
clinical atopy.
The decline in IgE anti-Derp1 observed following
treatment in the present study is consistent with findings
in Gabon (12). These authors reported a significant
increase in skin sensitization, while allergen-specific IgE
slightly declined, over the course of a 30 months of
PZQ –mebendazole treatment for helminth-infected chil-
dren.
Because atopy is inversely associated with schistosome
infection (2,19,48), this decline in allergen-specific IgE
may reflect the mechanisms involved in PZQ -associated
desensitization (49). These authors demonstrated that
blood basophils from S. mansoni-infected individuals were
desensitized to schistosome egg and worm antigens after
treatment. Sensitized basophils release histamine and cyto-
kines, including IL-4 capable of inducing Th2-IgE
responses (50,51). Furthermore, it has been shown that
serum IgE levels are closely related to FceRI expression
on basophils (52,53). Therefore, basophil desensitization
may have impacted on the levels of Derp1 IgE reported in
the current study.
However, because anti-schistosome IgE increased, it is
also possible that the polyclonal stimuli of ‘cross-reactive’
IgE, characteristic of helminth infections (54–56), has
been removed with treatment and a more specific anti-
parasite response produced. This is in line with findings
that anti-schistosome chemotherapy induces qualitative
changes in serological recognition of parasite antigen (16)
and increases cellular reactivity to parasite antigens
(17,57,58).
The lack of changes in the allergen-specific responses in
the low infection area is not surprising because the rela-
tionship between atopic responses and schistosome infec-
tion was weak due to low levels of infection intensity (19).
In the previous study, we demonstrated that it was heavy
infections that were associated with lower levels of atopy.
Thus, treating this population with low levels of schisto-
some infections would have less impact on both the para-
site-specific responses and atopic responses.
Several studies have been conducted in different popu-
lations investigating the effects of anti-helminthic treat-
ment on atopy. These studies have reported different
effects from having no effect on (13), worsening (12) and
improving (9) atopy. Potential explanations for these dif-
ferences include different parasite phyla (nematodes vs.
trematodes), infection intensity (low vs. high) and envi-
ronmental factors (59–62). Thus, meta-analyses approach
and comparative studies such us our present studies are
powerful in addressing the effects of heterogeneities in
this complex association between atopy and helminth
infection.
Taken together, these findings show that within
6 weeks, a single dose of PZQ treatment can affect schis-
tosome-specific and allergen-specific IgE and IgG4
responses. However, the effects of PZQ treatment on
these responses depend on schistosome endemicity levels.
Thus, in a high infection area, PZQ treatment can
increase antibody levels associated with resistance to
schistosome infection ⁄ re-infection while decreasing the
levels of sensitization to the house dust mite. With the
current WHO recommendations to implement control
programs in all endemic areas for schistosomiasis, this
study highlights the need to investigate the effect of treat-
ment at different levels of endemicity to predict long-
term consequences of deworming. There was no evidence
from this study to suggest that chemotherapeutic treat-
ment for schistosomiasis may exacerbate atopic responses
in endemic areas. The study does not preclude the possi-
bility that deworming may impact on allergic diseases
and further longer term longitudinal comparative studies
are required.
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